MaxCyte (MXCT) Share Price, News & Analysis

Company Overview

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Key Stats

• Today's Range: 279 to 284
• 50-Day Range: 275 to 340
• 52-Week Range: 248 to 430
• Volume: 11,605 shs
• Average Volume: 23,219 shs
• Market Capitalization: £297.40 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MXCT Stock Analysis - Frequently Asked Questions

How have MXCT shares performed this year?

MaxCyte's stock was trading at GBX 352.50 on January 1st, 2024. Since then, MXCT shares have decreased by 19.7% and is now trading at GBX 283.
View the best growth stocks for 2024 here.

How do I buy shares of MaxCyte?

Shares of MXCT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of MaxCyte own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MaxCyte investors own include HSBC (HSBA), Royal Dutch Shell (RDSB), Cassava Sciences (SAVA), EQTEC (EQT), Grafton Group (GFTU), Lloyds Banking Group (LLOY) and Marks and Spencer Group (MKS).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Medical Devices
• Sub-Industry: Business Services
• Current Symbol: LON:MXCT
• CUSIP: N/A
• CIK: N/A
• Web: www.maxcyte.com
• Phone: +1-301-9441700
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.26)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-35,430,000.00
• Net Margins: -77.97%
• Pretax Margin: N/A
• Return on Equity: -15.33%
• Return on Assets: -11.07%

Debt

• Debt-to-Equity Ratio: 8.37
• Current Ratio: 14.31
• Quick Ratio: 14.38

Sales & Book Value

• Annual Sales: £45.44 million
• Price / Sales: 6.54
• Cash Flow: GBX 143.51 per share
• Price / Cash Flow: 1.97
• Book Value: GBX 211 per share
• Price / Book: 1.34

Miscellaneous

• Outstanding Shares: 105,090,000
• Free Float: N/A
• Market Cap: £297.40 million
• Optionable: Not Optionable
• Beta: 1.13